大黄牡丹汤联合抗生素治疗急性憩室炎:随机对照试验研究方案
本研究为一项双组、随机、双盲、安慰剂对照、多中心试验,旨在评估大黄牡丹汤(DBT)联合静脉抗生素治疗中重度急性憩室炎的有效性和安全性。符合条件的受试者将随机接受10天口服DBT方案加常规治疗或10天安慰剂方案加常规治疗。主要结局为治疗成功率,定义为所有患者4天内腹痛消除,以及入组时发热(体温≥37.5°C)患者3天内体温降至<37.5°C。
要点
- DBT联合静脉抗生素可能提高中重度急性憩室炎的治疗成功率。
- 主要结局包括4天内腹痛消除和3天内退热。
- 次要结局涵盖住院天数、炎症指标变化、复发率及不良事件率。
核心结论
- 本试验旨在探讨静脉抗生素联合口服DBT是否较静脉抗生素联合安慰剂能更显著改善中重度急性憩室炎。
研究设计与样本
- 研究设计为双组、随机、双盲、安慰剂对照、多中心试验。
- 受试者随机接受10天口服DBT方案加常规治疗或10天安慰剂方案加常规治疗。
主要发现
- 主要结局为治疗成功率:所有患者4天内腹痛消除,入组时发热(体温≥37.5°C)患者3天内体温降至<37.5°C。
- 次要结局包括住院天数、炎症反应变化(CRP、WBC和中性粒细胞计数)、发热类型、开始进食前天数、复发率(注册后观察1年)和不良事件表达率。
- 评估在基线和出院日进行,复发率在注册后1年记录。
临床怎么用
- 若试验证实有效,DBT联合静脉抗生素可能成为中重度急性憩室炎的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Colonic diverticular disease has been increasing in prevalence due to the rapidly aging global population, but standard treatment has not changed dramatically in recent years. Daiobotanpito (DBT; Da Huang Mu Dan Tang in Chinese) has been used in medical treatment of acute abdominal abscesses, such as appendicitis or diverticulitis in traditional Japanese (Kampo) medicine for many years, based on more than 3000 years of experience. Prior to this study, a retrospective open-label trial was conducted to compare patients with acute diverticulitis who received oral DBT combined with intravenous antibiotics with those who received intravenous antibiotic alone; it showed a positive effect of DBT on acute diverticulitis. We aim to investigate whether moderate to severe acute diverticulitis shows greater improvement with intravenous antibiotics plus orally administered DBT compared with intravenous antibiotics plus placebo. METHODS: This is a two-group, randomized, double-blind, placebo-controlled, multi-center trial, which is designed to evaluate the efficacy and safety of DBT in patients with moderate to severe diverticulitis treated with intravenous antibiotics. Eligible participants will be randomized to either a treatment group receiving a 10-day oral DBT regimen plus conventional therapy or a control group receiving a 10-day placebo regimen plus conventional therapy. The primary outcome will be success in treating diverticulitis: the success rate will be defined as elimination of abdominal pain within 4 days in all patients, and in patients with fever (body temperature ≧ 37.5 °C) on inclusion into this study, fever relief with reduction in body temperature to < 37.5 °C within 3 days. Secondary endpoints will include the number of hospitalization days, changes in inflammatory response (C-reactive protein (CRP), white blood cell (WBC) and neutrophil counts), fever type, number of days before beginning food intake, recurrence rate (observation for 1 year after registration), and adverse event expression rate. Assessments will be performed at baseline and on the day of discharge. The recurrence rate will be recorded at 1 year after registration. DISCUSSION: This study is expected to provide evidence to support the clinical benefits of DBT in the treatment of acute diverticulitis. It may also provide evidence on the efficacy and safety of DBT in the recurrence of acute diverticulitis. TRIAL REGISTRATION: UMIN-CTR: UMIN000027381. Registered on 27 April 2017. https://upload.umin.ac.jp/cgi-bin/ctr/ctr_view_reg.cgi?recptno=R000031377, and changed to jRCTs041180063, registered on 30 July 2019; as a result of the revision of the domestic law in 2018 in Japan.
引用
- Ogawa-Ochiai K, Yoshimura K, Shirai A, et al. Study protocol for daiobotanpito combined with antibiotic therapy for treatment of acute diverticulitis: a study protocol for a randomized controlled trial. Trials. 2020. PMID: 32546262. doi:10.1186/s13063-020-04370-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。